54P - Circulating prostate-specific antigen and telomere length in a nationally representative sample of men without history of prostate cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Prostate Cancer
Translational Research
Presenter Wahyu Wulaningsih
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors W. Wulaningsih1, Y. Astuti2, T. Matsuguchi3, P. Anggriyadanny4, J. Watkins5
  • 1Mrc Unit For Lifelong Health And Ageing, UCL - University College London, WC1B 5JU - London/GB
  • 2Surgery & Cancer, Imperial College London - Hammersmith Hospital, W12 0NN - London/GB
  • 3Department Of Biochemistry And Biophysics, University of California San Francisco, 94158 - San Francisco/US
  • 4Division Of Hematology/oncology, Gadjah Mada University/Dr. Sardjito General Hospital, 55284 - Yogyakarta/ID
  • 5Division Of Cancer Studies, King's College London Guy's Hospital, SE1 9RT - London/GB

Abstract

Background

We investigated the association of prostate-specific antigen (PSA) with leukocyte telomere length, which may be altered in preclinical prostate malignancies.

Methods

This study was based on the 2001-2002 USA National Health and Nutrition Examination Survey (NHANES). A subsample of 1,127 men aged 40-85 years without prior history of prostate cancer who provided informed consent and blood samples were selected. Leukocyte telomere length (LTL) relative to standard DNA reference (T/S ratio) was quantified by polymerase chain reaction (PCR). Survey-weighted multivariable linear regression was performed to examine T/S ratio across quintiles of total and free PSA and free-to-total PSA ratio (%fPSA). A sensitivity analysis was performed by excluding men dying from prostate cancer during follow-up through to 31 December 2006. Stratification analyses were carried out to assess any effect modification by age group, race, body mass index (BMI) and levels of C-reactive protein (CRP), a marker of inflammation.

Results

Higher total PSA levels were associated to longer LTL, with approximately 8% increase in log-transformed T/S ratio (95% confidence interval [CI]: 2-13%) among men in the highest quintile of total PSA compared to the lowest in the fully adjusted model (Ptrend=0.01). No significant association was found for free PSA or %fPSA, although nonlinearity between all PSA measures and T/S ratio was indicated. Similar results were found after excluding men who died from prostate cancer during follow-up. We also found the associations between total PSA and T/S ratio to be strongest among non-Hispanic blacks, non-obese men (BMI

Conclusions

Total PSA levels were strongly associated to leukocyte telomere length, particularly among non-Hispanic blacks. Our findings support a potential link between PSA and specific mechanisms contributing to prostate cancer development.

Clinical trial indentification

Legal entity responsible for the study

King\'s College London

Funding

PILAR Research and Education Foundation

Disclosure

All authors have declared no conflicts of interest.